Oruka Therapeutics, Inc.
6
3
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Role: lead
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Role: lead
ORKA-001 in Healthy Volunteers
Role: lead
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Role: lead
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Role: lead
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
Role: lead
All 6 trials loaded